Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Childhood Idiopathic Nephrotic Syndrome
NCT01268033Phase 3Completed
- Sponsor
- CHU de Limoges
- Start
- Dec 2010
- Primary completion
- May 2014
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in Idiopathic nephrotic syndrome (INS) comparing Rituximab with Placebo (2 arms). Primary endpoint: Proteinuria with relapse of nephrotic syndrome at 5 months. Started Dec 2010; status: completed.
02
Drugs
rituximab
03
Conditions
Idiopathic nephrotic syndrome (INS)
Beyond the preview
Go deeper on NCT01268033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01268033.